18-FDG PET in the staging and follow-up of lymphoma patients: Comparison with clinical and radiologic findings

18-FDG PET in the staging and follow-up of lymphoma patients: Comparison with clinical and radiologic findings (92 visite)

Mainolfi C, Maurea S, Varrella P, Alaia C, Imparato C, Alfano B, Abate G, Bazzicalupo L

Radiol Med (ISSN: 1826-6983, 0033-8362, 1826-6983electronic), 1998; 95(1-2): 98-104.

Tipo di articolo: Journal Article,

Impact factor: 0.967, Impact factor a 5 anni: 1.448

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0031615399&partnerID=40&md5=3044467f6e7ef95e15ddf8c1353c53a2

Parole chiave: Lymphomas, Diagnostic Imaging, Fdg Pet, Article, Cancer Localization, Cancer Staging, Diagnostic Value, Hodgkin Disease, Human, Major Clinical Study, Nonhodgkin Lymphoma, Positron Emission Tomography, Comparative Study, Computer Assisted Emission Tomography, Female, Follow Up, Radiography, Scintiscanning, Diagnostic Agent, Fluorodeoxyglucose F 18, Radiopharmaceutical Agent, Follow-Up Studies, Non-Hodgkin, Neoplasm Staging, Emission-Computed,

Affiliazioni:

Medicina Nucleare, Ctro. Med. Nucl. Cons. Naz. R., Univ. degli Studi Federico II, Napoli, Italy
Via Raffaele De Cesare 7, 80132 Napoli NA, Italy

Riferimenti:

Bekerman, C., Hoffer, P.B., Bitran, J.D., The role of gallium-67 in the clinical evaluation of cancer (1984) Semin Nucl Med, 14, pp. 296-32

Bergonzini, R.E., Vezzolt, G., Rossi, G., I linfomi maligni a localizzazione toracica: Problemi di semeiologia e stadiazione radiologica (1988) Radiol Med, 76, pp. 56-63

Ellert, J., Kreel, L., The role of Computed Tomograph in the initial and subsequent management of the lymphomas (1980) JCAT, 4, pp. 368-391

Gasparini, M., Indicatori a tropismo tumorale (1994) Progressi Della Medicina Nucleare in Oncologia, pp. 129-175. , Buraggi GL, Bombardieri E (eds): Clas International. Brescia

Hatanaka, M., Transport of sugars in tumor cell membranes (1974) Biochem Biophys Acta, 355, pp. 77-104

Hoh, C.K., Glaspy, J., Rosen, P., Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphomas (1997) J Nucl Med, 38, pp. 343-348

Martiat, Ph., Ferrant, A., Labar, D., In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography (1988) J Nucl Med, 29, pp. 1633-1637

Negendank, W.G., Al-Katib, A.M., Karanes, C., Lymphomas: MR Imaging contrast characteristics with clinical pathological correlations (1990) Radiology, 177, pp. 209-216

Newman, J.S., Francis, I.R., Kaminski, M.S., Imaging of lymphoma with PET with 2-F-18-fluoro-2-deoxy-D-glucose: Correlation with CT (1994) Radiology, 190, pp. 111-116

Paul, R., Comparison of Fluorine-18-2-Fluorodeoxygiucose and gallium-67 citrate imaging for detection of lymphoma (1987) J Nucl Med, 28, pp. 288-292

Rigo, P., Paulus, P., Kaschten, B.J., Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose (1996) Eur J Nucl Med, 23, pp. 1641-1674

Schonberger, J.A., Stollfuss, J.C., Kocher, F., Whole-body 18-FDG-PET for staging of malignant lymphomas (1994) Eur J Nucl Med, 21, p. 727

Leskinen-Kallio, S., Ruotsalainen, U., Nagren, K., Uptake of carbon-11-Methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study (1991) J Nucl Med, 32, pp. 1211-1218

Strauss, L.G., Conti, P.S., The applications of PET in clinical oncology (1991) J Nucl Med, 32, pp. 623-648

Turner, D.A., Fordham, E., Ali, A., Gallium 67 imaging in the management of Hodgkin's disease and other malignant lymphomas (1978) Semin Nucl Med, 8, pp. 205-218

Valk, P.E., Pounds, T.R., Tesar, R.D., Cost-effectiveness of PET imaging in clinical oncology (1996) Nucl Med Biol, 23, pp. 737-743

Wahl, R.L., Hawkins, R.A., Larson, S.M., Proceeding of a national cancer institute workshop: PET in oncology - A clinical research agenda (1994) Radiology, 193, pp. 604-606

Wahl, R.L., Hutchins, G.D., Buchsboaum, D.J., 18-F-2-deoxy-2-fluoro-deoxyglucose uptake into human tumor xenografts (1991) Cancer, 67, pp. 1544-1550

Warburg, O., On the origin of cancer cells (1956) Science, 123, pp. 309-314

Weinhous, S., Changing perceptions of carbohydrate metabolism in tumors (1981) Molecular Interrelations of Nutrition and Cancer, pp. 167-181. , Arnott MS, Van Eys SJ, Wary JM (eds): Raven Press. New York

Bergonzini, R. E., Vezzolt, G., Rossi, G., I linfomi maligni a localizzazione toracica: Problemi di semeiologia e stadiazione radiologica (1988) Radiol Med, 76, pp. 56-63

Hoh, C. K., Glaspy, J., Rosen, P., Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphomas (1997) J Nucl Med, 38, pp. 343-348

Negendank, W. G., Al-Katib, A. M., Karanes, C., Lymphomas: MR Imaging contrast characteristics with clinical pathological correlations (1990) Radiology, 177, pp. 209-216

Newman, J. S., Francis, I. R., Kaminski, M. S., Imaging of lymphoma with PET with 2-F-18-fluoro-2-deoxy-D-glucose: Correlation with CT (1994) Radiology, 190, pp. 111-116

Schonberger, J. A., Stollfuss, J. C., Kocher, F., Whole-body 18-FDG-PET for staging of malignant lymphomas (1994) Eur J Nucl Med, 21, p. 727

Strauss, L. G., Conti, P. S., The applications of PET in clinical oncology (1991) J Nucl Med, 32, pp. 623-648

Turner, D. A., Fordham, E., Ali, A., Gallium 67 imaging in the management of Hodgkin's disease and other malignant lymphomas (1978) Semin Nucl Med, 8, pp. 205-218

Valk, P. E., Pounds, T. R., Tesar, R. D., Cost-effectiveness of PET imaging in clinical oncology (1996) Nucl Med Biol, 23, pp. 737-743

Wahl, R. L., Hawkins, R. A., Larson, S. M., Proceeding of a national cancer institute workshop: PET in oncology - A clinical research agenda (1994) Radiology, 193, pp. 604-606

Wahl, R. L., Hutchins, G. D., Buchsboaum, D. J., 18-F-2-deoxy-2-fluoro-deoxyglucose uptake into human tumor xenografts (1991) Cancer, 67, pp. 1544-1550

Introduction. The clinical applications of fluorine-18-deoxyglucose Positron Emission Tomography (FDG PET) have been proposed on account of experimental evidence of increased glucose metabolism in tumor cells. Material and methods. We examined 98 lymphoma patients - 33 with Hodgkin and 65 with non-Hodgkin disease - with FDG PET and compared its findings with those of clinical and conventional radiologic studies. FDG PET was also used to follow-up 32 patients and the results were once again compared with clinical and radiologic data. Results. During staging, 138 lesions were found, 82 of them (59%) in nodal and 56 (41%) in extranodal locations. Extranodal tumor sites were found in 39 patients (40%), namely 4 with Hodgkin (12%) and 35 with non-Hodgkin (54%) disease. FDG PET findings were in agreement with clinical and radiologic results in all nodal and extranodal lesions, since all of them exhibited abnormally increased FDG uptake. PET detected new tumor sites in 6 patients. In the follow-up, agreement was observed in the majority (78%) of lesions, 30 of them in complete regression, 15 in partial regression and 17 in progression; however, the diagnostic results were in disagreement in the remaining (22%) tumor sites: no abnormal FDG uptake was found in 9 cases despite the persistence of radiologic abnormalities (post-treatment fibrosclerosis). Slightly increased FDG uptake (residual disease) was found in the other 8 lesions, where there was no clinical and/or radiologic evidence of disease. Conclusions. FDG PET is a functional imaging technique useful to diagnose lymphomas and providing metabolic characterization of cancer abnormalities. Whole body PET permits the simultaneous assessment of nodal and extranodal lymphoma localizations. During the follow-up, FDG PET permits better monitoring of treatment effects than clinical and radiologic examinations.